Abstract
In the past few years macromolecular crystallography has become a standard technique used by many pharmaceutical and biotechnology companies. This methodology offers details of protein-ligand interactions at levels of resolution virtually unmatched by any other technique, and this approach holds the promise of novel, more effective, safer and cheaper drugs. Although crystallography remains a laborious and rather expensive technique, remarkable advances in structure determination and structure based drug design (SBDD) have been made in recent years. This process has been aided by recent technological innovations such as high-throughput crystallization, high performance synchrotron beamlines, and new methods in structural bioinformatics and computational chemistry prompted by the structural genomics effort. As a consequence of the increased availability of structural data, the use of structure-based information has expanded from simple protein-ligand interaction analysis to include other aspects of the drug discovery process like target selection and initial lead discovery that used to be almost the exclusive property of biology and chemistry. This review will cover recent examples to illustrate how macromolecular crystallography has evolved and how structural information is now being used in the different stages of the drug discovery process. Advantages and shortcomings of the methodology will also be discussed.
Keywords: computational method, De novo ligand generation, Src SH2 inhibitor, virtual screening, lead optimization, Pentostatin
Current Pharmaceutical Design
Title: Structural Biology and Drug Discovery
Volume: 12 Issue: 17
Author(s): Giovanna Scapin
Affiliation:
Keywords: computational method, De novo ligand generation, Src SH2 inhibitor, virtual screening, lead optimization, Pentostatin
Abstract: In the past few years macromolecular crystallography has become a standard technique used by many pharmaceutical and biotechnology companies. This methodology offers details of protein-ligand interactions at levels of resolution virtually unmatched by any other technique, and this approach holds the promise of novel, more effective, safer and cheaper drugs. Although crystallography remains a laborious and rather expensive technique, remarkable advances in structure determination and structure based drug design (SBDD) have been made in recent years. This process has been aided by recent technological innovations such as high-throughput crystallization, high performance synchrotron beamlines, and new methods in structural bioinformatics and computational chemistry prompted by the structural genomics effort. As a consequence of the increased availability of structural data, the use of structure-based information has expanded from simple protein-ligand interaction analysis to include other aspects of the drug discovery process like target selection and initial lead discovery that used to be almost the exclusive property of biology and chemistry. This review will cover recent examples to illustrate how macromolecular crystallography has evolved and how structural information is now being used in the different stages of the drug discovery process. Advantages and shortcomings of the methodology will also be discussed.
Export Options
About this article
Cite this article as:
Scapin Giovanna, Structural Biology and Drug Discovery, Current Pharmaceutical Design 2006; 12 (17) . https://dx.doi.org/10.2174/138161206777585201
DOI https://dx.doi.org/10.2174/138161206777585201 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Azo Dye Degrading Enzyme Research
Current Protein & Peptide Science An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases
Current Drug Targets Patent Selections
Recent Patents on Nanotechnology Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors
Current Pharmaceutical Design DNA Demethylating Agents and Chromatin-Remodelling Drugs: Which, How and Why?
Current Drug Metabolism Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry Network Systems Underlying Traditional Chinese Medicine Syndrome and Herb Formula
Current Bioinformatics Diet After Cholecystectomy
Current Medicinal Chemistry Barriers to Optimising Prescribing and Deprescribing in Older Adults with Dementia: A Narrative Review
Current Clinical Pharmacology Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Current Drug Safety Identification of Cancerlectins by Split Bi-profile Bayes Feature Extraction
Current Proteomics Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry